<scp>DNL</scp>104, a Centrally Penetrant <scp>RIPK</scp>1 Inhibitor, Inhibits <scp>RIP</scp>1 Kinase Phosphorylation in a Randomized Phase I Ascending Dose Study in Healthy VolunteersHendrika W. Grievink, Geert Jan Groeneveld|Clinical Pharmacology & Therapeutics|2019Cited by 77
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trialPepijn Eijsvogel, Jean‐Cosme Dodart, Yueh-Ting Hsieh et al.|Nature Medicine|2024Cited by 38
The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravisMartin Skov, Thomas Holm Pedersen, Titia Q. Ruijs et al.|Science Translational Medicine|2024Cited by 31